Publicacións en colaboración con investigadores/as de Hospital Universitario Lucus Augusti (2)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

2020

  1. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

    Lung Cancer, Vol. 150, pp. 62-69